Organization
The First Affiliated Hospital of Xi'an Jiaotong University, Xi 'an, China
8 abstracts
Abstract
Tislelizumab plus sitravatinib as adjuvant therapy for patients with hepatocellular carcinoma at high risk of recurrence after surgical resection: Preliminary analysis of a multi-center, non-randomized, open-label phase 2 study.Org: The First Affiliated Hospital of USTC, Hefei, China, The First Affiliated Hospital of Guangxi Medical University, Nanning, China, The First Affiliated Hospital of Xi'an Jiaotong University, Xi 'an, China, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China,
Abstract
Tislelizumab combined with chemotherapy or radiotherapy as neoadjuvant therapy for resectable esophageal squamous cell carcinoma (TINES): A randomized, open, phase II study.Org: Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Guangzhou, China, Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China, Nanfang Hospital, Southern Medical University, Guangzhou, China, The First Affiliated Hospital of Xi'an Jiaotong University, Xi 'an, China, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China,
Abstract
Single-cell and bulk sequencing analysis to evaluate the oncogenic role of PDE3A in pan-cancer and validation in breast cancer.Org: The First Affiliated Hospital of Xi'an Jiaotong University, Xi 'an, China, The First Affiliated Hospital of Xian Jiaotong University, Xi'an, China, The First Affiliated Hospital of Xi’an Jiaotong University,
Abstract
Axillary lymph nodes pCR (apCR) versus breast pCR (bpCR): A meta-analysis involving 10,723 patients.Org: The First Affiliated Hospital of Xi'an Jiaotong University, Xi 'an, China, Xian, China, The First Affiliated Hospital of Xi’an Jiaotong University, Xi'an, China,
Abstract
Safety and preliminary efficacy of YK-029A, a novel EGFR TKI, in patients with advanced NSCLC harboring ex20ins, T790M or rare mutations.Org: State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Science,Peking Union Medical College, Chinese Academy of Medical Sciences and Peking Union Medical College, Peking University Cancer Hospital and Institute (Beijing Cancer Hospital), Beijing, China, Peking Union Medical College Hospital, Academy of Medical Sciences & Peking Union Medical College, Beijing, China,
Abstract
Huaier granules for hepatocellular carcinoma recurrence after ablation: A multicenter prospective cohort study.Org: National Cancer Center Hospital East, Kashiwa, Japan, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, Beijing Youan Hospital, Capital Medical University, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China,
Abstract
IMM27M, a humanized Fc-engineered anti CTLA-4 antibody, in patients with advanced solid tumors: A phase I dose-escalation study.Org: Sun Yat-sen University Cancer Center Gansu Hospital, Harbin Medical University Cancer Hospital, Henan Cancer Hospital, Peking University First Hospital, The First Affiliated Hospital of Xi'an Jiaotong University, Xi 'an, China,
Abstract
A phase Ib/II, open-label, multicenter study to evaluate the safety, efficacy, and pharmacokinetics/pharmacodynamics of αvβ3/5 integrin and neuropilin-1 targeting peptide LSTA1 in patients with metastatic pancreatic ductal adenocarcinoma.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, The Fifth Medical Center of Chinese PLA General Hospital, Department of Gastroenterology and Urology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China, Harbin Medical University Cancer Hospital,